By Ismail Auwal
The COVID-19 vaccine developed by a Chinese based firm in Beijing was found to have a protection rate of 79.3% against the virus.
The vaccine is linked to a subsidiary of the China National Biotec Group Co Ltd (CNBG) called Sinopharm’s vaccine and bioscience.
The firm said it had applied to the National Medical Products Administration for conditional approval of the vaccine.
The result is based on an interim analysis of data from its phase III clinical trial, but the firm did not give details such as the number of infections in the trial.
